LB Pharmaceuticals (NASDAQ:LBRX) Price Target Raised to $40.00 at Stifel Nicolaus

LB Pharmaceuticals (NASDAQ:LBRX) had its price target increased by Stifel Nicolaus from $35.00 to $40.00 in a report published on Friday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings reissued a “sell (e)” rating on shares of LB Pharmaceuticals in a research report on Monday, December 29th. Roth Mkm assumed coverage on LB Pharmaceuticals in a research report on Friday, January 9th. They issued a “buy” rating and a $31.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

LB Pharmaceuticals Stock Down 2.8%

NASDAQ LBRX opened at $23.84 on Friday. The firm has a 50 day simple moving average of $23.59. The firm has a market capitalization of $603.15 million and a P/E ratio of -39.08. LB Pharmaceuticals has a 12-month low of $13.36 and a 12-month high of $27.55.

LB Pharmaceuticals (NASDAQ:LBRX) last announced its earnings results on Thursday, March 26th. The company reported ($0.45) EPS for the quarter, hitting the consensus estimate of ($0.45).

Institutional Trading of LB Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. acquired a new stake in LB Pharmaceuticals in the fourth quarter valued at $244,000. XTX Topco Ltd grew its position in shares of LB Pharmaceuticals by 69.6% in the 4th quarter. XTX Topco Ltd now owns 19,121 shares of the company’s stock valued at $426,000 after acquiring an additional 7,845 shares during the period. Logos Global Management LP increased its stake in shares of LB Pharmaceuticals by 6.2% during the 4th quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $26,712,000 after purchasing an additional 70,000 shares during the last quarter. RA Capital Management L.P. raised its holdings in shares of LB Pharmaceuticals by 24.3% in the 4th quarter. RA Capital Management L.P. now owns 2,208,604 shares of the company’s stock valued at $49,164,000 after purchasing an additional 431,646 shares during the period. Finally, California State Teachers Retirement System bought a new stake in shares of LB Pharmaceuticals in the 4th quarter valued at about $26,000.

Trending Headlines about LB Pharmaceuticals

Here are the key news stories impacting LB Pharmaceuticals this week:

• Positive Sentiment: Initiated pivotal Phase 3 NOVA-2 trial for LB-102 in acute schizophrenia, moving the program into late‑stage development and de‑risking the clinical pathway. LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102
• Positive Sentiment: New Phase 2 (NOVA-1) analyses presented at SIRS show LB-102 produced statistically significant, likely direct improvements in cognitive performance versus placebo — a clinically meaningful differentiation if confirmed in Phase 3. LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial
• Positive Sentiment: Multiple SIRS presentations and encore sessions underline broad evidence across symptom domains (positive, negative, cognitive), increasing the perceived clinical value of LB-102. LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial (GlobeNewswire)
• Positive Sentiment: Stifel raised its price target from $35 to $40 and maintains a Buy rating — a notable analyst vote of confidence that can support upside if clinical and regulatory progress continues. Stifel raises price target
• Positive Sentiment: Strong cash position: ~$295.2M in cash, equivalents and investments as of 12/31/25 plus ~$100M private placement; company says runway into Q2 2029 — reduces near‑term financing risk for ongoing trials. Q4 and FY2025 Results and Corporate Update
• Neutral Sentiment: Q4 EPS of ($0.45) matched consensus — earnings met expectations but did not provide an upside catalyst; full financials and guidance appear consistent with the company’s stated runway. Quarterly Results PDF
• Negative Sentiment: Cautionary forward‑looking statements and standard clinical/regulatory risks remain — Phase 3 outcomes, approval risk and commercialization execution are not guaranteed, and the company has a limited operating history and historical losses. Risk Factors and Cautionary Note

LB Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.